2019 David Chu Lecture

Translation of In Vitro Transporter Data into the Clinic
Presented by Kathleen Hillgren, PhD
Drug Disposition, Lilly Research Laboratories, Indianapolis, IN

Tuesday, April 30
4:30 – 6:00 p.m.
190 Kapoor Hall

Kathleen Hillgren, PhD.

Dr. Hillgren is a Research Fellow in the Investigative Drug Disposition Group at Lilly Research laboratories. She received her doctorate in Pharmaceutical Chemistry from the University of Kansas and then spent two years at the University of California at San Francisco as a postdoctoral fellow.

After her fellowship, Dr. Hillgren worked at Rhone-Poulenc Rorer in the Department of Drug Metabolism and Pharmacokinetics where she was responsible for coordinating the preclinical development of drug candidates and in vitro drug absorption models. Dr. Hillgren joined Eli Lilly in 1999.

Since joining Lilly, she founded and grew the drug transport group. Her research interests include prediction of clinical drug-drug interactions at transporters, transporter pharmacogenomics and utilization of intestinal transporters for drug delivery.

The lecture will be followed by a reception in the Panasci Atrium.

About David Chu

C. K. David Chu, PhD, and his wife, Jane Chu, established the David Chu Lectureship at UB in 2011. 

David Chu.

C.K. David Chu

David Chu is a distinguished research professor emeritus of pharmaceutical and biomedical sciences at the College of Pharmacy, University of Georgia. He earned a PhD in medicinal chemistry from the University at Buffalo in 1975 under the mentorship of Professor Thomas Bardos. Dr. Chu was one of the co-founders of Pharmasset and ATEA Pharmaceuticals.  During his 40-year career, Dr. Chu trained more than 130 graduate students and postdoctoral fellows and has maintained an active research program in drug design and synthesis since his retirement in 2008.  He has published over 300 peer-reviewed articles in organic, biochemical and medicinal chemistry and has been awarded more than 60 US patents. Several of his invented compounds are undergoing clinical trials in the therapeutic areas of cancer, hepatitis B virus, HIV and shingles.

An elected member of the American Association of Advancement of Science and the National Academy of Inventors, Dr. Chu received the Antonin Holy Memorial Lecture Award from the International Society Antiviral Research and the Willis G. Gregory Award from the UB School of Pharmacy in 2017.  He also received the Alma Mater of the Year Award from Seoul National University in 2015, the John A. Montgomery Award from the International Round Table Society in 2014, a MERIT Award from the National Institute of Health in 2001, and the UGA Inventor of the Year Award in 2002.

Previous Lectures

Peter Senter, Vice President of Chemistry at Seattle Genetics, Inc.
Antibody-based therapeutics for cancer therapy: An early stage research to a clinically approved drug

Lisa Benincosa, PhD '93
Evolution of Translational PK/PD: A Pharma Perspective

John Eng, MD
A Drug Discovery

Hank Kung, PhD
Development of Imaging Agents for Diagnosing Alzheimer’s Disease

A. Douglas Kinghorn, PhD
The Enduring Contribution of Natural Products to the Pharmaceutical Sciences

Wolfgang Sadee, PhD
Optimizing Drug Therapy on Person at a Time: How will Pharmacogenomics Succeed

Christopher Lipinski, PhD
Drug Discovery and Chemical Biology: Lessons Learned and Times of Change